Effect of a Baduanjin Exercise plus nutrition programme on Cancer-Related Fatigue in Elderly Patients with Lung Cancer Undergoing Chemotherapy: A Randomized Controlled Trial

Start Date01 Jul 2024

Sponsor / Collaborator

Zhejiang Hospital

NCT06488391 / RecruitingNot ApplicableIIT

The Impact of Patients' Daily Independent Breathing Training on the Accuracy and Side Effects of Deep Inspiratory Breath-Hold Radiotherapy for Breast Cancer

Breast cancer DIBH (Deep Inspiration Breath Hold) radiotherapy represents a high-precision treatment approach that substantially minimizes radiation exposure to vital organs such as the heart, thus enhancing protection of the patient's heart, lungs, contralateral breast, and other normal tissues compared to conventional radiotherapy techniques. This method requires meticulous precision, necessitating that patients possess exceptional respiratory control, which is facilitated through specialized equipment. Without such control, patients may encounter issues like missed targets, significant setup errors, and extended treatment durations.
In this study, the research team employed portable devices to enable patients to independently perform daily respiratory training exercises. The control group received no such devices; instead, these patients were merely instructed verbally on the importance of improving their breath-holding capabilities. The effectiveness of this intervention was evaluated by comparing the daily setup errors between the two groups. Additionally, the intervention's influence on patient outcomes was assessed by monitoring the toxicity and side effects experienced by the patients.

Start Date01 Jun 2024

Sponsor / Collaborator

Zhejiang Hospital

NCT06570655 / Active, not recruitingPhase 1

The Study of Pharmacokinetics and Pharmacodynamics of Huperzine A Injection in Healthy Chinese Subjects

The study used a single-center, open, sequential single-dose design. To evaluate the pharmacokinetics and dose-exposure relationship of huperzine A injection

Start Date16 May 2024

Sponsor / Collaborator

Wepon Pharmaceuticals Group Co. Ltd.

[+1]

100 Clinical Results associated with Zhejiang Hospital

0 Patents (Medical) associated with Zhejiang Hospital

1,849

Literatures (Medical) associated with Zhejiang Hospital

31 Dec 2024·Redox Report

Nobiletin protects against alcohol-induced mitochondrial dysfunction and liver injury by regulating the hepatic NRF1-TFAM signaling pathway

Article

Author: Lu, Dan ; Zhang, Xiaoyan ; Tong, Xiaoqing ; Huang, Aiping ; Yu, Xiaolong ; Li, Songtao

OBJECTIVESAlcohol and its metabolites, such as acetaldehyde, induced hepatic mitochondrial dysfunction play a pathological role in the development of alcohol-related liver disease (ALD).METHODSIn this study, we investigated the potential of nobiletin (NOB), a polymethoxylated flavone, to counter alcohol-induced mitochondrial dysfunction and liver injury.RESULTSOur findings demonstrate that NOB administration markedly attenuated alcohol-induced hepatic steatosis, endoplasmic reticulum stress, inflammation, and tissue damage in mice. NOB reversed hepatic mitochondrial dysfunction and oxidative stress in both alcohol-fed mice and acetaldehyde-treated hepatocytes. Mechanistically, NOB restored the reduction of hepatic mitochondrial transcription factor A (TFAM) at both mRNA and protein levels. Notably, the protective effects of NOB against acetaldehyde-induced mitochondrial dysfunction and cell death were abolished in hepatocytes lacking Tfam. Furthermore, NOB administration reinstated the levels of hepatocellular NRF1, a key transcriptional regulator of TFAM, which were decreased by alcohol and acetaldehyde exposure. Consistent with these findings, hepatocyte-specific overexpression of Nrf1 protected against alcohol-induced hepatic Tfam reduction, mitochondrial dysfunction, oxidative stress, and liver injury.CONCLUSIONSOur study elucidates the involvement of the NRF1-TFAM signaling pathway in the protective mechanism of NOB against chronic-plus-binge alcohol consumption-induced mitochondrial dysfunction and liver injury, suggesting NOB supplementation as a potential therapeutic strategy for ALD.

01 Dec 2024·International Immunopharmacology

Schisandrin C inhibits AKT1-regulated cell proliferation in A549 cells

Article

Author: Wang, Zhisen ; Xie, Shengyang ; Liu, Zhengcheng ; Zhou, Wencheng ; Li, Li

BACKGROUNDLung cancer is the leading cause of cancer-related mortality. Cancer poses a significant challenge to human health and remains a persistent and pressing issue. Schisandrin C is one of the active ingredients of Schisandra chinensis and has various biological and pharmacological activities. This study aimed to investigate the effects of Schisandrin C on lung cancer and the underlying mechanism involved.METHODSA network pharmacology strategy was used to screen the target genes and pathways involved in the relationship between Schisandrin and lung cancer. Next, a single-cell RNA sequencing (scRNA-seq) assay revealed the expression of genes specifically expressed in lung cancer epithelial cells. A549 cells were subsequently treated with Schisandrin C for 24 h or 48 h, cell viability was assessed via MTT and EdU staining experiments, and target gene expression was measured via RT-qPCR and immunofluorescence assays. Moreover, lung cancer patient tissues were observed via multiplex immunofluroscence staining.RESULTSAKT1, CA9, BRAF, EGFR, ERBB2 and PIK3CA were overlapping target genes for network pharmacology and the scRNA-seq strategy. In vitro, the RT-qPCR results indicated that Schisandrin C inhibited the mRNA expression of the AKT1, CA9, FASN, MMP1, EGFR and BRAF genes. In clinical samples from patients with lung cancer, the expression levels of CA9 and AKT1 were found to be significantly higher in lung tumor tissues than in the adjacent normal (TAN) tissues. Moreover, the administration of an AKT kinase inhibitor reversed the inhibitory effect of Schisandrin C on A549 cells proliferation, whereas the administration of a CA9 inhibitor failed to have a similar effect.CONCLUSIONSSchisandrin C effectively suppressed the proliferation and viability of A549 cells. Its mechanism was related to the inhibition of the AKT1 signaling pathway.

01 Dec 2024·Biomaterials

Camouflaging nanoreactor traverse the blood-brain barrier to catalyze redox cascade for synergistic therapy of glioblastoma

Article

Author: Ye, Peng ; He, Li ; Bao, Dandan ; Wu, Zhibing ; Wu, Yajun ; Lai, Jianjun ; Yue, Tianxiang ; Ren, WeiYe ; Piao, Ji-Gang ; Cheng, WeiYi ; Wei, YingHui

The blood-brain barrier (BBB) is a complex and highly restrictive barrier that prevents most biomolecules and drugs from entering the brain. However, effective strategies for delivering drugs to the brain are urgently needed for the treatment of glioblastoma. Based on the efficient BBB penetration properties of exosomes derived from brain metastatic breast cancer cells (EB), this work prepared a nanoreactor (denoted as MAG@EB), which was constructed by self-assembly of Mn²⁺, arsenate and glucose oxidase (GOx) into nanoparticles wrapped with EB. MAG@EB can enhance the efficiency of traversing the BBB, target and accumulate at in situ glioblastoma sites. The GOx-driven glycolysis effectively cuts off the glucose supply while also providing an abundance of H₂O₂ and lowering pH. Meanwhile, the released Mn²⁺ mediated Fenton-like reaction converts elevated H₂O₂ into highly toxic ·OH. Besides, AsV was reduced to AsIII by glutathione, and the tumor suppressor gene P53 was activated by AsIII to kill glioblastoma cells. Glioblastoma succumbed to the redox cascade triggered by MAG@EB, as the results demonstrated in vivo and in vitro, yielding a remarkable therapeutic effect. This work provides a promising therapeutic option mediated by cascaded nanoreactors for the future treatment of glioblastoma.

News (Medical) associated with Zhejiang Hospital

16 Feb 2023

·www.globenewswire.com

Predicine to Present Four Studies at 2023 ASCO Genitourinary (GU) Symposium Highlighting the Technical and Clinical Utility of Predicine’s Liquid Biopsy Based Assays

HAYWARD, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Predicine, a global molecular insights company, is committed to advancing genitourinary (GU) cancer detection and treatment decisions through its proprietary non-invasive next-generation sequencing (NGS) assays. Predicine’s technology aims to help provide translational insights and key information through: Identification of actionable variants in bladder cancer using the PredicineCARETM urine cfDNA NGS assay, a non-invasive molecular diagnostic test Clinical application of copy number variations (CNV) monitoring in bladder cancer and prostate cancer using PredicineCNBTMMinimal Residual Disease (MRD) detection and monitoring in Non-Muscle Invasive Bladder Cancer (NMIBC) using a personalized and actionable MRD assay, PredicineBEACONTM Predicine will present four posters at the ASCO Genitourinary Cancers Symposium, February 16-18, 2023, highlighting the technical and clinical utility of Predicine's suite of liquid based comprehensive genomic solutions in bladder, prostate tumors. The posters to be presented include: Evaluating the technical feasibility of a urine cell-free DNA (cfDNA) NGS assay for identifying biomarkers in bladder cancer - Poster BD# N8 (collaboration with Janssen Pharmaceuticals)Diagnoses of prostate cancer using cell-free DNA methylation profiles from expressed prostatic secretions - Poster BD# N6 (collaboration with Zhejiang Hospital)Clinical applications of urine and blood-based genome wide copy number study from 1000 bladder and prostate cancer patients - Poster BD# G19Cell-free urinary tumor DNA to detect minimal residual disease prior to repeat-transurethral resection of bladder tumor in non-muscle-invasive bladder cancer: A prospective study - Poster BD# C1 (collaboration with Moffitt Cancer Center and Research Institute, Merit Award) “Liquid biopsy has revolutionized our ability to diagnose, monitor and guide therapy for genitourinary cancers. At Predicine, we are proud to be pioneering the development and use of liquid biopsy technology to drive forward clinical trial and companion diagnostics development. Our portfolio of innovative products and services and recent FDA Breakthrough Device Designation are testaments to our commitment to transforming healthcare through precision medicine", said Dr. Shidong Jia, Founder & Global CEO. Additional peer-reviewed publications and posters can be found on Predicine’s website here. About PredicinePredicine is a global molecular insights company that is committed to advancing precision medicine in oncology, and infectious disease diagnostics. Predicine is developing proprietary cell-free DNA- and cell-free RNA-based liquid biopsy technologies to enable minimally invasive molecular diagnosis for early cancer detection, treatment selection, therapy response, minimal residual disease monitoring and disease progression. The Predicine portfolio includes blood, urine, and tissue based NGS assays designed for global harmonized use in research, clinical investigation, and CDx development. Through its business operations in Silicon Valley, Houston, Chicago, Boston, Shanghai, Singapore, Beijing, Suzhou, and Harbin, Predicine is partnering and collaborating with leading biopharma companies, institutions, and governments to support personalized healthcare on a global scale. Further information is available on the company’s website, http://www.predicine.com and www.covid19.predicine.com. Stay in touch on LinkedIn or @Predicine on Twitter.Contact Information: Predicine, Inc.media@predicine.com

Clinical Study

100 Deals associated with Zhejiang Hospital

100 Translational Medicine associated with Zhejiang Hospital

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 08 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

Current Projects

Drug(Targets)	Indications	Global Highest Phase

CN113577268 ( HSP )	Solid tumor More	Discovery

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis